Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M30,719Revenue $M2,105Net Margin (%)20.2Z-Score19.3
Enterprise Value $M30,601EPS $3.8Operating Margin %36.1F-Score4
P/E(ttm))84.4Cash Flow Per Share $-2.0Pre-tax Margin (%)33.9Higher ROA y-yN
Price/Book13.910-y EBITDA Growth Rate %0Quick Ratio5.9Cash flow > EarningsY
Price/Sales14.95-y EBITDA Growth Rate %0Current Ratio6.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %42.4ROA % (ttm)14.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)21.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M101ROI % (ttm)53.3Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 304.51-1%Add 23.47%1,743,468
REGNFrank Sands 2014-03-31 Add0.22%$267.62 - $347.62
($307.2)
$ 304.51-1%Add 7.48%4,012,062
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 304.51-1%New holding, 6084 sh.6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 304.516%Sold Out0
REGNFrank Sands 2013-09-30 Add0.56%$227.65 - $309.174
($262.76)
$ 304.5116%Add 20.34%3,777,357
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 304.5116%New holding, 3285 sh.3,285
REGNRay Dalio 2013-09-30 Sold Out -0.01%$227.65 - $309.174
($262.76)
$ 304.5116%Sold Out0
REGNFrank Sands 2013-06-30 Add1.07%$178.51 - $282.8
($232.86)
$ 304.5131%Add 81.03%3,138,793
REGNRay Dalio 2013-06-30 Buy 0.01%$178.51 - $282.8
($232.86)
$ 304.5131%New holding, 4100 sh.4,100
REGNVanguard Health Care Fund 2013-03-31 Add0.62%$158.42 - $183.77
($171.66)
$ 304.5177%Add 170.41%1,412,100
REGNFrank Sands 2013-03-31 Reduce-1.02%$158.42 - $183.77
($171.66)
$ 304.5177%Reduce -46.22%1,733,896
REGNFrank Sands 2012-09-30 Reduce-1.2%$112.77 - $152.66
($135.2)
$ 304.51125%Reduce -37.57%3,834,373
REGNVanguard Health Care Fund 2012-09-30 Reduce-0.09%$112.77 - $152.66
($135.2)
$ 304.51125%Reduce -24.56%522,200
REGNFrank Sands 2012-06-30 Add0.2%$108.78 - $143.87
($125.43)
$ 304.51143%Add 6.5%6,142,048
REGNDodge & Cox 2012-03-31 Sold Out $57.83 - $119.96
($92.23)
$ 304.51230%Sold Out0
REGNCarl Icahn 2011-09-30 Sold Out -1.76%$44.96 - $72.19
($58.66)
$ 304.51419%Sold Out0
REGNDodge & Cox 2011-09-30 Reduce-0.03%$44.96 - $72.19
($58.66)
$ 304.51419%Reduce -97.62%9,400
REGNDodge & Cox 2011-03-31 Buy 0.02%$32.61 - $44.68
($36.41)
$ 304.51736%New holding, 375685 sh.375,685
REGNSeth Klarman 2011-03-31 Sold Out $32.61 - $44.68
($36.41)
$ 304.51736%Sold Out0
REGNSeth Klarman 2010-09-30 Buy 1.66%$21.36 - $26.74
($24.02)
$ 304.511168%New holding, 1000000 sh.1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
REGN Ron Baron 2014-03-316,0840.010.01New Buy
REGN Vanguard Health Care Fund 2014-03-311,743,4681.731.5+23.47%
REGN Frank Sands 2014-03-314,012,0623.983.1+7.48%
Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-07-15Buy129,100$314.92-3.76view
Sanofi10% Owner 2014-07-14Buy300,000$316.8-4.33view
Sanofi10% Owner 2014-07-10Buy175,000$311.08-2.57view
Sanofi10% Owner 2014-07-09Buy348,000$309.76-2.15view
Sanofi10% Owner 2014-07-07Buy356,700$312.37-2.97view
Sanofi10% Owner 2014-07-02Buy212,400$307.25-1.35view
Sanofi10% Owner 2014-07-01Buy212,400$300.20.96view
Sanofi10% Owner 2014-06-30Buy262,400$281.177.8view
Van Plew Daniel PSVP & General Mgr Industrial O 2014-05-23Sell5,369$295.932.42view
POON CHRISTINE ADirector 2014-05-21Buy255$291.93.83view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 
    Weekly Top Insider Sells: REGN May 27 2013 
    comment on REGN Mar 06 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
    Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
    52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 
    52-Week High Companies: EC, MAT, ORLY, V, REGN Apr 16 2012 
    Weekly Top Insider Sells: TJX, MON, REGN, and PNC Jan 16 2012 

    More From Our Partners
    Stock Market News for July 24, 2014 - Market News Jul 24 2014 - ZACKS

    More From Other Websites
    Regeneron Pharmaceuticals Inc Stock Upgraded (REGN) Jul 25 2014
    Celgene, Alexion Beat Estimates, But Biotechs Fall Jul 24 2014
    Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG Jul 24 2014
    Aced the SAT? Try this Cramer question Jul 23 2014
    Biogen Idec: Biggest Beat in 10 Years, Largest Leap in Eight Months Jul 23 2014
    Bayer/Regeneron Continue to Progress with Eylea Jul 22 2014
    Coverage initiated on Regeneron Pharms by Argus Jul 21 2014
    Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and... Jul 18 2014
    Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and... Jul 18 2014
    Gilead Sciences: Time For a Dividend? Jul 18 2014
    InsiderInsights.com Daily Round Up: 7/17/14 Jul 18 2014
    Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment... Jul 18 2014
    Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment... Jul 18 2014
    SHPG, REGN And LLY, 3 Drugs Stocks Pushing The Industry Lower Jul 16 2014
    Gilead Sciences: The Senate Just Wrote Me a Letter Jul 11 2014
    Sanofi/Regeneron Announce Encouraging Dupilumab Data Jul 10 2014
    Regeneron's Dupilumab Drug Headed For Phase Three Tests Jul 10 2014
    Regeneron Picked a Heck of a Day to Announce Good News Jul 10 2014
    Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) Jul 10 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide